-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Acute respiratory distress syndrome (ARDS), are serious infections , shock, trauma and burns and other disease processes, pulmonary capillary vascular endothelial cells and diffuse alveolar damage in alveolar epithelial cells in inflammatory damage caused, leading to acute hypoxic respiratory Insufficiency or failure.
Infected blood vessels
The pharmaceutical company Foresee announced today that its highly selective oral MMP-12 inhibitor FP-025 will be used to treat severe COVID-19 patients with acute respiratory distress syndrome (ARDS) in a Phase II/III clinical trial in adult patients.
COVID-19
The Phase II/III clinical trial is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of FP-025.
Dr.
FP-025 has shown significant therapeutic effects in preclinical inflammation and pulmonary fibrosis models, which indicates that FP-025 may avoid lung damage and fibrosis caused by COVID-19 infection.
Original source:
Original source:href="" target="_blank" rel="noopener">leave a message here